Veer Biotechnology Inc. And GlaxoSmithKline plc’s COVID-19 antibody treatment worked against Omicron in a laboratory study, reflecting the latest announcement that research is underway to counter the new variant.
The companies said Tuesday that an in vitro study showed that their monoclonal antibody is active against Omicron, which has 37 mutations on the spike protein. The antibody treatment, sotrovimab, received authorization from the Food and Drug Administration in May.
Shares rose 4.2% in trading on Tuesday, while shares of GlaxoSmithKline GSK,
were up 0.4%.
“We are confident that sotrovimab will continue to provide significant benefits for the early treatment of patients hoping to avoid the most severe consequences of COVID-19,” Veer CEO George Scangos said in a statement.
The emergence of Omicron in recent weeks has set off a chain reaction between COVID-19 drug and vaccine manufacturers, who are now conducting laboratory studies evaluating how well their treatments and shots work against Omicron. work.
Other manufacturers of monoclonal antibodies have also said they are trying to see if their treatments will work against the new variant. Regeneron Pharmaceuticals Inc. REGN,
Officials told analysts last week that they expected his treatment to be “potent against Omicron”, with more data expected in the coming weeks. Eli Lilly & Company Inc. LLY,
3 said it is assessing “the neutralization activity of our treatments on the Omicron version of anxiety”.
Latest COVID-19 Numbers
The daily average number of cases in the US rose to 119,751 on Monday, the highest since September 25 and a 28% increase from two weeks ago. A New York Times Tracker, The daily average death toll rose 13% to 1,266, the highest since November 4. The number of hospitalizations rose 18% to a seven-week high of 59,702.
About 199.3 million people in the US, or 60%, are fully vaccinated, According to the Centers for Disease Control and Prevention, About 23% of the population has received a booster dose.
Other COVID-19 news to know:
The World Health Organization said on Tuesday that it no longer supports convalescent plasma as a treatment for COVID-19 patients. “Plasma administration, especially to patients with non-serious disease where there is a low baseline risk of mortality and other significant clinical outcomes, is not appropriate,” the organization written in bmj, The treatment is also considered ineffective in the US, based on test result A National Institutes of Health clinical trial.
Europeans will now have the option to “mix and match” their COVID-19 vaccines, Following a new recommendation from the European Medicines Agency and the European Center for Disease Prevention and Control. agencies said on tuesday that receiving a viral vector vaccine and then an mRNA shot produces “good levels of antibodies” as well as a “high T-cell response” whether the mixture is in the primary series or with a booster.
International travelers will now have to test a negative a day before flying to the US starting Monday. The less than 72 hour window to obtain a pre-flight test is intended to protect people in the US, while more information is obtained on the Omicron version, according to CDC,